• Home
  •  / Tempest Therapeutics

Tempest Therapeutics

OverviewSuggest Edit

Tempest Therapeutics is a development-stage biotechnology company advancing small molecules that modulate anti-tumor immunity pathways. The Company has a balanced and deep pipeline consisting of first-in-class and potential best-in-class small molecule therapeutics that modulate distinct immune response pathways relevant to mounting an effective anti-tumor response.

TypePrivate
HQSan Francisco, CA, USMap
Websitetempesttx.com

Recent NewsAll News

Latest Updates

Employees (est.) (Jun 2021)16(+7%)

Key People/Management at Tempest Therapeutics

Tom Dubensky

Tom Dubensky

Chief Executive Officer, Director
Stephen Brady

Stephen Brady

President and Chief Operating Officer
Sam Whiting

Sam Whiting

Chief Medical Officer
Chan Whiting

Chan Whiting

Senior Vice President, Research and Development
Sharon Sakai

Sharon Sakai

Senior Vice President, Regulatory Affairs
Anne Moon

Anne Moon

Vice President, Head of Project Team Leadership, Project Management and Portfolio Management
Show more

Tempest Therapeutics Office Locations

Tempest Therapeutics has offices in San Francisco and South San Francisco
San Francisco, CA, US (HQ)
One Sansome Street, 1 Sansome St #3690, San Francisco
South San Francisco, CA, US
7000 Shoreline Ct #275
Show all (2)

Tempest Therapeutics Financials and Metrics

Summary Metrics

Tempest Therapeutics total Funding

$70 m

Tempest Therapeutics latest funding size

$70 m

Time since last funding

3 years ago

Tempest Therapeutics investors

Versant Ventures, Foresite Capital, F-Prime Capital Partners, Eight Roads Ventures, Lilly Asia Ventures, Quan Capital
Tempest Therapeutics's latest funding round in March 2018 was reported to be $70 m. In total, Tempest Therapeutics has raised $70 m
Show all financial metrics

Tempest Therapeutics Online and Social Media Presence

Tempest Therapeutics's Trends

Embed Graph

Tempest Therapeutics News and Updates

May 27, 2021

Tempest Therapeutics to Present at the Jefferies Healthcare Conference

SOUTH SAN FRANCISCO, Calif., May 27, 2021 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc., a clinical-stage oncology company developing first-in-class therapeutics that combine both precision and immune-mediated mechanisms, today announced that management will be presenting at the Jefferies Healthc…
March 08, 2021

Tempest Therapeutics to Present at the Solebury Trout/Credit Suisse/Cooley Private Company Showcase

SOUTH SAN FRANCISCO, Calif., March 08, 2021 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc., a clinical-stage oncology company developing first-in-class therapeutics that combine both precision and immune-mediated mechanisms, today announced that management will be presenting at the 9th Solebury Tr…
March 03, 2021

Tempest Therapeutics Announces Clinical Collaboration with Roche to Advance TPST-1120 into a Randomized Combination Study in First-line Hepatocellular Carcinoma

TPST-1120/atezolizumab/bevacizumab triplet will be compared to atezolizumab/bevacizumab alone TPST-1120/atezolizumab/bevacizumab triplet will be compared to atezolizumab/bevacizumab alone
January 08, 2021

Tempest Therapeutics to Present at the H.C. Wainwright Virtual BioConnect Conference

SOUTH SAN FRANCISCO, Calif., Jan. 08, 2021 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc., a clinical-stage oncology company developing first-in-class therapeutics that combine both precision and immune-mediated mechanisms, today announced that Tom Dubensky, Ph.D., chief executive officer, and Ste…
January 07, 2021

Tempest Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc., a clinical-stage oncology company developing first-in-class therapeutics that combine both precision and immune-mediated mechanisms, today announced that Tom Dubensky, Ph.D., chief executive officer, Steve B…

 Tempest Therapeutics Frequently Asked Questions

  • Who are Tempest Therapeutics key executives?

    Tempest Therapeutics's key executives are Tom Dubensky, Stephen Brady and Sam Whiting.

  • How many employees does Tempest Therapeutics have?

    Tempest Therapeutics has 16 employees.

  • Who are Tempest Therapeutics competitors?

    Competitors of Tempest Therapeutics include ANA Therapeutics, Commonwealth Biotechnologies and Broad Institute.

  • Where is Tempest Therapeutics headquarters?

    Tempest Therapeutics headquarters is located at One Sansome Street, 1 Sansome St #3690, San Francisco, San Francisco.

  • Where are Tempest Therapeutics offices?

    Tempest Therapeutics has offices in San Francisco and South San Francisco.

  • How many offices does Tempest Therapeutics have?

    Tempest Therapeutics has 2 offices.